login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
RESMED INC (RMD) Stock News
NYSE:RMD -
US7611521078
-
Common Stock
273.81
USD
+4.6 (+1.71%)
Last: 9/4/2025, 8:04:00 PM
272.66
USD
-1.15 (-0.42%)
After Hours:
9/4/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RMD Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Chartmill
ResMed Inc. (NYSE:RMD): A Top Dividend Stock for Sustainable Income and Growth
9 days ago - By: Chartmill
- Mentions:
FCX
SJM
DXCM
WSM
...
These S&P500 stocks are gapping in today's session
a day ago - By: Resmed, Inc.
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
a day ago - By: Resmed, Inc.
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
2 days ago - By: Zacks Investment Research
- Mentions:
MASI
PAHC
NVST
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
9 days ago - By: Zacks Investment Research
Here's Why ResMed (RMD) is a Strong Growth Stock
9 days ago - By: Resmed, Inc.
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
9 days ago - By: Resmed, Inc.
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
10 days ago - By: Yahoo Finance
Is Wall Street Bullish or Bearish on ResMed Stock?
15 days ago - By: Resmed, Inc.
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
15 days ago - By: Resmed, Inc.
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
17 days ago - By: Resmed, Inc.
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
17 days ago - By: Resmed, Inc.
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
21 days ago - By: Zacks Investment Research
- Mentions:
LIVN
INSP
NYXH
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
23 days ago - By: Zacks Investment Research
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
25 days ago - By: Zacks Investment Research
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
25 days ago - By: Zacks Investment Research
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
a month ago - By: The Motley Fool
ResMed RMD Q4 2025 Earnings Call Transcript
a month ago - By: Benzinga
The Analyst Verdict: ResMed In The Eyes Of 8 Experts
a month ago - By: Benzinga
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings
a month ago - By: Zacks Investment Research
- Mentions:
BSX
MEDP
WGS
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
a month ago - By: Zacks Investment Research
Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings
a month ago - By: Zacks Investment Research
- Mentions:
OMI
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
a month ago - By: Resmed, Inc.
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
a month ago - By: Resmed, Inc.
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
Please enable JavaScript to continue using this application.